Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

Fig. 3

Survival analysis according to the combined expression pattern of PARP1, γH2AX, BRCA1, and BRCA2 in osteosarcomas. a Receiver operator characteristic curve analysis for the CSddrm (Combined Scores for the DNA damage response molecules PARP1, γH2AX, BRCA1, and BRCA2). CSddrm ranged from zero to four according to the number of positive markers, and the cut-off point (arrow) was three. CSddrm 3–4 includes the cases positive for three or four markers. b Kaplan-Meier survival analysis for the overall survival and relapse-free survival in the CSddrm 0–2 and CSddrm 3–4 sub-groups of osteosarcoma. c Kaplan-Meier survival analysis in low-stage (stage I and II) osteosarcomas according to the CSddrm subgroups of osteosarcoma

Back to article page